Cover Image
Market Research Report
Product code
1032062

Lyme Disease - Pipeline Insight, 2021

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Lyme Disease - Pipeline Insight, 2021
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

DelveInsight's, "Lyme Disease - Pipeline Insight, 2021," report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lyme Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Lyme Disease Understanding

Lyme Disease: Overview

Lyme disease is the most common vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

"Lyme Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lyme Disease pipeline landscape is provided which includes the disease overview and Lyme Disease treatment guidelines. The assessment part of the report embraces, in depth Lyme Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lyme Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Lyme Disease R&D. The therapies under development are focused on novel approaches to treat/improve Lyme Disease.

Lyme Disease Emerging Drugs Chapters

This segment of the Lyme Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lyme Disease Emerging Drugs

  • VLA 15: Valneva

VLA15 is currently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15. As part of its collaboration with Pfizer, Valneva accelerated the pediatric development of VLA15 with an additional Phase 2 clinical trial initiated in March 2021. In July 2021, Pfizer and Valneva announced recruitment completion for VLA15-221 with a total of 625 participants, 5 to 65 years of age. The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017

  • CT38: Cortene

CT38 is a potent, short-lived, peptide agonist selective for CRFR2. It is comprised entirely of naturally-occurring amino acids. It was tested in animals and in healthy humans in a Phase 1 clinical trial. These studies have defined the safety profile of CT38 in humans and show that CT38 only lasts a few hours in the body.

Further product details are provided in the report……..

Lyme Disease: Therapeutic Assessment

This segment of the report provides insights about the different Lyme Disease drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Lyme Disease

There are approx. 7+ key companies which are developing the therapies for Lyme Disease. The companies which have their Lyme Disease drug candidates in the most advanced stage, i.e. phase II include, Valneva.

  • Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Lyme Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lyme Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lyme Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lyme Disease drugs.

Lyme Disease Report Insights

  • Lyme Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Lyme Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Lyme Disease drugs?
  • How many Lyme Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lyme Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lyme Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lyme Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Valneva
  • Cortene
  • Flightpath Biosciences
  • Introvacc
  • Inovio Pharmaceuticals
  • Greffex
  • Abzyme Therapeutics
  • Tarus Pharmaceuticals

Key Products

  • VLA 15
  • CT38
  • FP-101
  • OspA-OMV based lyme vaccine
  • Research programme: DNA-based monoclonal antibody therapeutics
  • Lotilaner
Table of Contents
Product Code: DIPI0637

Table of Contents

Introduction

Executive Summary

Lyme Disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Lyme Disease - DelveInsight's Analytical Perspective

Mid Stage Products (Phase II)

  • Comparative Analysis

VLA 15: Valneva

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

CT 38: Cortene

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Lyme disease vaccine - Introvacc

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Lyme Disease Key Companies

Lyme Disease Key Products

Lyme Disease- Unmet Needs

Lyme Disease- Market Drivers and Barriers

Lyme Disease- Future Perspectives and Conclusion

Lyme Disease Analyst Views

Lyme Disease Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Lyme Disease
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Lyme Disease
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products